ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Gut Bacteria, Artificial Sweeteners and Glucose Intolerance

Reverse Mitochondrial Damage

Culprits of Autism Identified: Toxins, Gut Bacteria, Nutritional Deficiencies, and Vaccines Made wit...

Turmeric compound boosts regeneration of brain stem cells

CoQ10: The Longevity Factor

Magnesium: Widespread Deficiency with Deadly Consequences

Use of Broad-Spectrum Antibiotics Before Age 2 Associated with Obesity Risk

Is Homocysteine Making You Sick?

Extending Life and Fighting Disease with Resveratrol

VIDEO: Beautiful Clouds - Relaxation and Meditation

 
Print Page
Email Article

Another look at esreboxetine: 4th Rx alternative for fibromyalgia?

  [ 51 votes ]   [ Discuss This Article ]
www.ProHealth.com • July 26, 2012


A paper published in the July 2012 issue of Arthritis & Rheumatism...
Suggests a renewed investment interest by Pfizer Inc. in trials of its investigational drug esreboxetine as an FM therapy. (See “Safety and efficacy of esreboxetine in patients with Fibromyalgia: A 14-week, randomized, double-blind, placebo-controlled, multicenter clinical trial,” by University of Cincinnati fibromyalgia researcher Lesley M Arnold, MD, and a team at the UK-based Pfizer Global Research and Development organization.) 

For specifics not offered in the abstract of this fee-based paper...
See MedPageToday's physician CME report (“Novel Drug Helped in Fibromyalgia”).

By way of background, in Feb 2009...
Pfizer announced that they were discontinuing phase 3 trials of esreboxetine after their review of existing phase 2 trial data indicated the drug was unlikely to “provide meaningful benefit to patients beyond” other fibromyalgia Rx therapies that were already FDA approved (including Pfizer’s Lyrica, aka pregabalin). The average pain score improvement in trials of the drugs had been in the neighborhood of 30% or more, about what the new Arnold, et al. paper reports.

Now, however, at least two factors have entered the mix:

• The big three FDA approved fibromyalgia drugs will be coming off patent starting Oct 2013 with Lyrica, opening this huge multi-billion-dollar market to competition from generally lower price generics. For example, on July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals. At the same time, industry analysts predict "huge market opportunities" for pharmaceutical companies owing to increased FM awareness, diagnosis rates, and market penetration. 

• And second, it is suggested that the new research reflects physician/patient experience over the past few years demonstrating that responses to/side effects of the approved drugs – and to different combinations of those drugs – differ, sometimes significantly, from patient to patient. A factor that may overcome regulatory preference for a focus on drugs to treat unmet needs.

Currently, for example, a trial at the University of Utah is recruiting fibro patients to determine if differences in blood biomarkers can be linked to different responses to Lyrica (pregabalin) therapy.

Each of the approved drugs - and reboxetine - involves a different mechanism of action (albeit sometimes not entirely understood).
 
• Unlike the three currently approved drugs, esreboxetine is “a highly-selective norepinephrine reuptake inhibitor”: that is, it concentrates only norepinephrine in the brain.

• Savella (milnacipran) and Cymbalta (duloxetine) concentrate both serotonin and norepinephrine, though by different means.

• Lyrica (pregabalin) is said to decrease the release of the neurotransmitters substance P and glutamate, and “restore” release of norepinephrine.

So overall it seems fibromyalgia and neuropathic pain patients and their physicians can expect to see continued FM drug research, by Dr. Arnold at the University of Cincinnati and others.



Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Vitamins and Supplements

Featured Products

Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
Optimized Curcumin Longvida® by ProHealth Optimized Curcumin Longvida® by ProHealth
Supports Cognition, Memory & Overall Health
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid

Natural Remedies

Preserving Cognitive Function with Aging Preserving Cognitive Function with Aging
Are You Obtaining the Proper Enzymes? Are You Obtaining the Proper Enzymes?
How I Found My Long-Lost Energy How I Found My Long-Lost Energy
The Brain Boosting and Fatigue Fighting B-12 The Brain Boosting and Fatigue Fighting B-12
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing